December 14, 2005 – After the closing bell, Amgen announced it would buy Abgenix, its partner on two drugs, for $22.50 per share; Arena Pharma reported positive data from a 3-month study of its obesity drug, APD356; Idenix released data showing that valopicitabine was effective against hepatitis C; SciClone announced that Zadaxin did not meet its endpoints in a hepatitis C trial; Voyager Pharma officially withdrew its IPO application; Epix Pharma will cut its workforce by 50%; Human Genome Sciences will spin off its CoGenesys division next year; American Pharmaceutical Partners won FDA approval for a generic equivalent to Zithromax from Pfizer; and Maxygen earned a $5 million milestone from Roche. The Centient Biotech 200™ was 27 points lower at 3978.19, a loss of .69%. More details...
